Inuvair Nexthaler (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Inuvair Nexthaler is a combination inhaled corticosteroid and long‑acting β2‑agonist used for chronic respiratory conditions.

• Asthma: improves long‑term control of symptoms and reduces exacerbations in persistent asthma.
• Chronic obstructive pulmonary disease (COPD): provides maintenance bronchodilation and anti‑inflammatory effect to lessen symptom burden.
• Chronic bronchitis (as part of COPD): helps reduce airway inflammation and improve airflow in patients with chronic bronchitic phenotype.

• Beclometasone dipropionate binds to intracellular glucocorticoid receptors, modulating gene transcription to suppress airway inflammation. Formoterol activates β2‑adrenergic receptors on bronchial smooth muscle, increasing cyclic AMP and causing rapid, sustained bronchodilation. The combined actions provide both anti‑inflammatory and bronchodilatory effects, improving lung function and symptom control in asthma and COPD.

Inhaled corticosteroid/long‑acting β2‑agonist therapy may cause a range of adverse reactions.

Common Side Effects

• Oral thrush (candidiasis): fungal infection of the mouth.
• Hoarseness or dysphonia: voice changes due to local steroid effect.
• Cough or throat irritation: irritation from inhaled powder.
• Headache: mild to moderate intensity.
• Nasal congestion: blockage of nasal passages.
• Muscle cramps: occasional skeletal muscle discomfort.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Pneumonia: especially in COPD patients.
• Adrenal suppression: reduced endogenous cortisol production.
• Glaucoma or cataracts: ocular pressure increase or lens opacity.
• Severe allergic reactions: anaphylaxis, angioedema, or urticaria.
• Osteoporosis: decreased bone mineral density with long‑term use.

Inuvair Nexthaler should be used according to prescriber instructions and with awareness of specific safety considerations.

• Assess infection risk: monitor for signs of respiratory infection, especially pneumonia in COPD.
• Monitor adrenal function: consider assessment in patients on high‑dose or prolonged therapy.
• Evaluate ocular health: periodic eye examinations for cataracts or glaucoma.
• Use with caution in pregnancy: limited data, weigh benefits against potential risks.
• Educate on inhaler technique: ensure proper use to minimize local side effects.
• Store below 30°C: keep in original packaging, protect from moisture and direct sunlight.

Inhaled corticosteroid/LABA combinations can interact with other medications, affecting safety or efficacy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic steroid exposure.
• Monoamine oxidase inhibitors (MAOIs): risk of additive cardiovascular effects with formoterol.

Moderate Interactions (Monitor Closely)

• β‑blockers: may reduce bronchodilator response of formoterol.
• Diuretics: potential for hypokalemia when combined with β2‑agonists.
• Anticholinergics: monitor for additive anticholinergic side effects.
• Other inhaled corticosteroids: avoid excessive glucocorticoid exposure.